Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 337

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 337
---
 disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report
on Form 8-K.

| 175 |

<div align='center'>INFORMATION ABOUT LONGEVITY</div>

Unless the context otherwise requires, all references in this section to “Longevity,” “we,” “us,” “our” or “the Company” refer to the business of Longevity Biomedical, Inc. and its proposed Targets prior to the consummation of the Business Combination, which will become the business of FutureTech following the consummation of the Business Combination. Further, unless the context requires otherwise, information presented herein with respect to the proposed Targets assumes that the Target Acquisitions have been consummated; however, there is no assurance that the Target Acquisitions will be consummated.

Company Overview

Longevity is
formed Delaware corporation that was incorporated in October 2021. We are a biopharmaceutical company focused on the advancement of impactful
new technologies and services across therapeutics, monitoring and digital health that address diseases associated with aging and were
formed to pursue acquisitions of target companies in the medical technology and biomedical life sciences industries. Our initial acquisitions,
the Target Acquisitions, are intended to advance solutions across well-defined areas of chronic age-related conditions associated with
degeneration of tissue form and function, beginning with therapeutic technologies across ophthalmology, soft-tissue reconstruction and
repair, and cardiovascular disease. Upon consummation of the Target Acquisitions and closing of the Business Combination, FutureTech will
be renamed “Longevity Biomedical, Inc.”

Building on this
initial platform of therapeutic technologies, we intend to opportunistically acquire and/or partner with other health technology companies
to become a leading provider and consolidator of products and services designed to increase and improve health span amongst the rapidly
growing aging patient population.

We are led by
a team of industry experts and scientific advisors with significant experience acquiring, developing, and commercializing cutting-edge
health technologies. Our management team is a critical component to the execution of our overall strategy and our business model. We have
assembled a team with significant experience in translational science, clinical development, regulatory affairs and business development.
We believe these capabilities will drive our ability to identify, acquire, develop and commercialize novel products and technologies in
the longevity field. We believe our expertise will make us the partner of choice for leading biopharmaceutical/medtech companies or academic
institutions that wish to maximize the value of their longevity product candidates